CTOR (Citius Oncology) Revenue: $5.61 Mil (TTM As of Mar. 2026)


CTOR Citius Oncology Inc CTOR
10 GF Score
Price $0.68
! 2 Warning Signs
View Full Analysis

What is Citius Oncology Revenue?

Citius Oncology CTOR -2.10% 10 Revenue is $5.61 Mil as of Mar. 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Citius Oncology's revenue for the three months ended in Mar. 2026 was $1.67 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $5.61 Mil. Citius Oncology's Revenue per Share for the three months ended in Mar. 2026 was $0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.06.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


Citius Oncology  (NAS:CTOR) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Citius Oncology Revenue Related Terms


Citius Oncology Revenue Historical Data

* Premium members only.

The historical data trend for Citius Oncology's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Oncology Revenue Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24 Sep25
Revenue
0.00 0.00 0.00 0.00

Citius Oncology Quarterly Data
Sep22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 3.94 1.67

CTOR vs INCR, TLPH, ETST: Revenue Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Citius Oncology Revenue vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Revenue distribution charts can be found below:

* The bar in red indicates where Citius Oncology's Revenue falls into.


CTOR
10GF Score
Citius Oncology Inc CTOR
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citius Oncology Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $5.61 Mil mean?
Citius Oncology (CTOR) has a Revenue of $5.61 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Citius Oncology and its competitors.
Is Citius Oncology's Revenue too high?
Citius Oncology's current Revenue is $5.61 Mil. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Revenue compare to INCR and TLPH?
Citius Oncology's Revenue of $5.61 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Citius Oncology and its competitors. Citius Oncology's current Revenue is $5.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Revenue of $5.61 Mil. The current Revenue is $5.61 Mil. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Revenue is $5.61 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Oncology Business Description

Address 11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score

Get the complete analysis for CTOR

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.68
Price